ION582

DRUG4 trials

Sponsors

Ionis Pharmaceuticals Inc., Ionis Pharmaceuticals, Inc.

Conditions

Angelman SyndromeAngelman syndrome

Phase 1

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

RecruitingNCT05127226

Ionis Pharmaceuticals, Inc.Angelman Syndrome

Start: 2021-12-22End: 2029-03-31Target: 70Updated: 2025-11-14

ION582-CS1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients with Angelman Syndrome

Not yet recruitingCTIS2024-512589-32-00

Ionis Pharmaceuticals Inc.Angelman syndrome

Target: 8Updated: 2025-12-05

Phase 3

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

RecruitingNCT06914609

Ionis Pharmaceuticals, Inc.Angelman Syndrome

Start: 2025-06-10End: 2030-04-01Target: 158Updated: 2026-05-15

REVEAL Study: Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome

Not yet recruitingCTIS2024-519711-33-01

Ionis Pharmaceuticals Inc.Angelman syndrome

Target: 14Updated: 2026-03-09